Conservative Treatment With Medroxyprogesterone Acetate Plus Levonorgestrel Intrauterine System for Early-Stage Endometrial Cancer in Young Women: Pilot Study. Issue 4 (1st April 2011)

• Record Type: Journal Article
• Authors: Kim, Mi Kyung; Yoon, Bo Sung; Park, Hyun; Seong, Seok Ju; Chung, Hyun Hoon; Kim, Jae Weon; Kang, Soon Beom
• Is Part Of: International journal of gynecological cancer. Volume 21:Issue 4(2011)
• Page Start: 673
• Page End: 677
• Publication Date: 2011-04-01
• Subjects: Endometrial cancer -- Progesterone -- LNG-IUS -- Medroxyprogesterone acetate -- Levonorgestrel; Generative organs, Female -- Cancer -- Periodicals; 616.99465
• DOI: 10.1111/IGC.0b013e3181fd9a06
• Languages: English
• ISSNs: 1048-891X

Abstract

Abstract : Objective: To assess the feasibility of using medroxyprogesterone acetate (MPA) and levonorgestrel intrauterine system (LNG-IUS) to treat early-stage endometrial cancer in young women who want to preserve their reproductive potential. Methods: Prospective observational study of 5 young patients (mean [SD] age, 38.4 [4.8] years; range, 33-41 years) with a grade 1 endometrial cancer that is presumably confined to the endometrium. The subjects were given a daily oral dose of 500 mg of MPA and LNG-IUS placement. They were followed with dilation and curettage every 3 months. Results: Complete remission was shown in 4 of 5 patients, and one patient showed partial remission. Biopsy results were negative in 2 patients at 3 months, in 1 patient at 6 months, and in 1 patient at 12 months. No treatment-related complications occurred. No recurrence was found during the follow-up period (mean [SD], 10.2 [3.6] months; range, 6-16 months). Conclusions: The concomitant use of MPA with LNG-IUS is feasible for conservative treatment of early-stage endometrial cancer in young women who want to preserve their reproductive potential.